A New fresh research report presented by KD Market research provides a detailed analysis of “Oral Proteins and Peptides Market “ research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The research provides a complete understanding of the “Oral Proteins and Peptides Market “ in terms of revenue.
The peptide and protein therapeutics are an important class of medicines, which are administered through the oral route to treat different diseases, which include gastric, hormonal, and metabolic disorders. These drugs hold significant potential to improve the human health. The global oral proteins and peptides market was valued at $643 million in 2016, and is estimated to reach at $8,233 million by 2028, registering a CAGR of 11.7% from 2022 to 2028.
Request For sample Copy of this Report @ https://www.kdmarketresearch.com/sample/3379
Upsurge in collaboration between pharmaceutical companies for drug development and surge in prevalence of chronic diseases are the key factors that augment the growth of the global oral proteins and peptides market. Moreover, rise in geriatric population and improvement in healthcare infrastructure are expected to boost the market growth.
However, low bioavailability of oral proteins and peptides and high cost associated with drug development are some of the factors that restrain the market growth. Conversely, increase in purchasing power of developing countries and rise in R&D activities by pharmaceutical companies are expected to provide new opportunities for market players in the near future.
The oral proteins and peptides market is segmented into drug type, application, and region. By drug type, the market is divided into linaclotide, plecanatide, calcitonin, insulin, and octreotide. By application, it is categorized into gastric & digestive disorders, bone diseases, diabetes, and hormonal disorders. Based on region, it is analyzed across the U.S. and rest of the world.
KEY BENEFITS FOR STAKEHOLDERS
-This report entails a detailed quantitative analysis of the current market trends and future estimations from 2016 to 2028 to identify the prevailing opportunities.
-The oral proteins and peptides market size and estimations are based on comprehensive analysis of the key developments in the industry.
-In-depth analysis based on region assists to understand the regional market and the strategic business planning.
-The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Drug Type
-Gastric & Digestive Disorders
-Rest of the world
The list of key players operating in this market includes:
-Proxima Concepts Limited (Diabetology Ltd.)
-Generex Biotechnology Corp.
-Novo Nordisk A/S
-Synergy Pharmaceuticals Inc.
-Tarsa Therapeutics Inc.
Browse Complete Research Report with toc@ https://www.kdmarketresearch.com/report/3379/oral-proteins-and-peptides-market-amr
Table of Content
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Clinical trials
3.4. Top player positioning, 2018
3.5. Patent analysis, 2010-2017
3.5.1. Patent analysis, by year (2010-2017)
3.5.2. Patent analysis, by country
3.6. Market dynamics
188.8.131.52. Increase in collaboration between pharmaceutical companies for drug development
184.108.40.206. Surge in prevalence of chronic diseases
220.127.116.11. Rise in geriatric population and improvement in healthcare infrastructure
18.104.22.168. Low bioavailability of oral proteins and peptides
22.214.171.124. High costs associated with drug development
126.96.36.199. Increase in purchasing power of emerging economics
188.8.131.52. Increase in R&D activities by pharmaceutical companies
CHAPTER 4: ORAL PROTEINS AND PEPTIDES MARKET, BY DRUG TYPE
4.1.1. Market size and forecast
4.2.1. Key market trends
4.2.2. Market size and forecast
4.3.1. Key market trends
4.3.2. Market size and forecast
4.4.1. Key market trends
4.4.2. Market size and forecast
4.5.1. Key market trends
4.5.2. Market size and forecast
4.6.1. Key market trends
4.6.2. Market size and forecast
CHAPTER 5: ORAL PROTEINS AND PEPTIDES MARKET, BY APPLICATION
5.1.1. Market size and forecast
5.2. Gastric & digestive disorders
5.2.1. Market size and forecast
5.3. Bone diseases
5.3.1. Market size and forecast
5.4.1. Market size and forecast
5.5. Hormonal disorders
5.5.1. Market size and forecast
CHAPTER 6: ORAL PROTEINS AND PEPTIDES MARKET, BY REGION
6.1.1. Market size and forecast
6.2.1. Key market trends
6.2.2. Market size and forecast
6.3. Rest of the world
6.3.1. Key market trends
6.3.2. Market size and forecast
CHAPTER 7: COMPANY PROFILES
7.1. Allergan Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. AstraZeneca PLC
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Product portfolio
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.3. Biocon Limited
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Chiasma Inc.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Product portfolio
7.4.4. Key strategic moves and developments
7.5. Generex Biotechnology Corp.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Key strategic moves and developments
7.6. Novo Nordisk A/S
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Oramed Pharmaceuticals Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Product portfolio
7.7.4. Key strategic moves and developments
7.8. Proxima Concepts Limited (Diabetology Ltd.)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.9. Synergy Pharmaceuticals Inc.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Product portfolio
7.9.4. Key strategic moves and developments
7.10. Tarsa Therapeutics Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Product portfolio
7.10.4. Key strategic moves and developments
Check Exclusive Discount on this Report@ https://www.kdmarketresearch.com/discount/3379
KD Market Research is one of the best market research organization that provides B2B research on the growth opportunities of the industry which is the prime factor of the overall revenue of the organization. We identify the pain points which our client is facing around revenue methods and provide them with a comprehensive database which helps them to make intelligent decisions that could ensure growth to the organization.
Our Services include market intelligence, competitive intelligence, and customized research. These research reports help the organizations to make quick and powerful decisions that make out highest growth in revenue.
Contact us -
KD Market Research
150 State Street, Albany,
New York, USA 12207
Email id- email@example.com